Adjuvant Global Health Technology Fund DE, L.P., 10% Owner at AN2 Therapeutics, Inc. (ANTX), sold 10,304 shares at $16.02 ($165K) on 2023-09-06, disclosed to the SEC on 2023-09-08.
Scheduled sale ($165k) by 10% Owner under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $16.02 | 598 | $10K | 5.8% |
| 2 | $16.02 | 3,164 | $51K | 30.7% |
| 3 | $16.02 | 3,164 | $51K | 30.7% |
| 4 | $16.05 | 537 | $9K | 5.2% |
| 5 | $16.05 | 2,841 | $46K | 27.6% |
| Total | $16.03 avg | 10,304 |
| $165K |
| 100% |
| Filing → |